Form 8-K - Current report:
SEC Accession No. 0001628280-25-023788
Filing Date
2025-05-08
Accepted
2025-05-08 16:09:03
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aadi-20250508.htm   iXBRL 8-K 28142
2 EX-99.1 aadi-20250508xex991.htm EX-99.1 79905
6 image.jpg GRAPHIC 11898
  Complete submission text file 0001628280-25-023788.txt   259546

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aadi-20250508.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aadi-20250508_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aadi-20250508_pre.xml EX-101.PRE 13040
17 EXTRACTED XBRL INSTANCE DOCUMENT aadi-20250508_htm.xml XML 2845
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38560 | Film No.: 25926074
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)